Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Overview
Currencies
International
Treasuries

Neogenomics Inc (NQ: NEO )

16.32 +0.55 (+3.49%)
Streaming Delayed Price Updated: 12:06 PM EST, Nov 11, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Neogenomics Inc

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
The Implications Behind Genetron Health's Latest Earnings Report
Image provided by Mentor Finance Genetron Holdings Limited (NASDAQ: GTH) recently announced its latest fiscal report, elaborating its progress in the oncology genetic testing... 
Via Benzinga
NeoGenomics To Participate In The Stephens Annual Investment Conference 2021
FT. MYERS, FL / ACCESSWIRE / November 30, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NASDAQ: NEO Shareholder Notice: Investigation over Potential Wrongdoing at NeoGenomics, Inc.
San Diego, CA -- (SBWIRE) -- 11/29/2021 -- An investigation on behalf of investors in NeoGenomics, Inc. (NASDAQ: NEO) shares over potential wrongdoing at NeoGenomics, Inc. was announced. 
Via SBWire
Exposures COVID-19
NASDAQ:NEO Investor Notice: Investigation over Possible Securities Laws Violations by NeoGenomics, Inc.
San Diego, CA -- (SBWIRE) -- 11/10/2021 -- NeoGenomics, Inc. is under investigation concerning possible violations of securities laws in connection with certain financial statements. 
Via SBWire
Exposures COVID-19
Where NeoGenomics Stands With Analysts
Over the past 3 months, 4 analysts have published their opinion on NeoGenomics (NASDAQ: 
Via Benzinga
Recap: NeoGenomics Q3 Earnings
NeoGenomics (NASDAQ:NEO) reported its Q3 earnings results on Thursday, November 4, 2021 at 08:00 AM. Here's what investors need to know about the announcement. Earnings... 
Via Benzinga
Recap: NeoGenomics Q2 Earnings
Shares of NeoGenomics (NASDAQ:NEO) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share were up 75.00% year over year to ($0.01),... 
Via Benzinga
NeoGenomics Appoints Dave Daly to Its Board of Directors
FT. MYERS, FL / ACCESSWIRE / November 10, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, has... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
NeoGenomics, inc (NEO) Q3 2021 Earnings Call Transcript
NEO earnings call for the period ending September 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NeoGenomics Reports Revenue of $121 Million in the Third Quarter
Third-Quarter 2021 Results and Highlights: - Consolidated revenue of $121 million, comprised of Clinical Services revenue of $102 million and Pharma Services revenue of $19 million - Consolidated... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance Retirement
Exposures COVID-19 Legal Pension
NeoGenomics Announces Leadership Team Transition
FT. MYERS, FL / ACCESSWIRE / November 4, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, announced... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
81 Biggest Movers From Yesterday
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares jumped 95.1% to close at $12.68 on Thursday after dropping over 10% on Wednesday. TDH Holdings, Inc. (NASDAQ: PETZ) jumped 79.8... 
Via Benzinga
55 Stocks Moving In Thursday's Mid-Day Session
Gainers Evaxion Biotech A/S (NASDAQ: EVAX) shares climbed 179% to $18.17 after dropping over 10% on Wednesday. NerdWallet, Inc. (NASDAQ: NRDS) jumped 60% to $28.86 after the... 
Via Benzinga
NeoGenomics' Liquid Biopsy Subsidiary Inivata Announces Clinical Collaboration With Princess Margaret Cancer Center for the Use of Its Liquid Biopsy Assays
Two clinical studies including interventional RaDaR™ study FT. MYERS, FL / ACCESSWIRE / October 19, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
The Daily Biotech Pulse: Merck's Oral COVID-19 Pill Authorized In UK, Novartis Cashes Out Of Roche, Chimerix Plunges On Data, Evotec IPO
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Merck's Oral Antiviral COVID-19 Pill Authorized In UK Merck &... 
Via Benzinga
Exposures COVID-19
NeoGenomics Schedules its Third Quarter 2021, Earnings Release for November 4, 2021
FT. MYERS, FL / ACCESSWIRE / October 13, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
The Week Ahead In Biotech (Oct. 31-Nov. 6): Earnings Pick Up Pace, Eton Awaits Seizure Drug Approval, Kidney Conference, More IPOs In The Pipeline
Biotech stocks rose a third week running in the week ending Oct. 29 amid positive reaction to earnings. Big pharma earnings were mostly better than expected. Merck & Co, Inc... 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 14, 2021
Upgrades According to Roth Capital, the prior rating for Ring Energy Inc (AMEX: 
Via Benzinga
NeoGenomics Announces Board of Directors' Transition
Appoints Lead Independent Director Lynn Tetrault as Non-Executive Chair. Douglas VanOort steps-down as Executive Chairman and will retire from the Board of Directors before the end of the year FT.... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance Retirement
Exposures COVID-19 Legal Pension
Guardant Health Will Not Go With NeoGenomics Deal: Bloomberg
Guardant Health Inc (NASDAQ: GH) has decided not to pursue a potential acquisition of NeoGenomics Inc (NASDAQ: NEO), Bloomberg reported citing people... 
Via Benzinga
Why Guardant Health Is Down More Than 14% Friday
Investors aren't fans of an acquisition the diagnostics company is rumored to be considering. 
Via The Motley Fool
Guardant Health Weighing NeoGenomics Acquisition: Bloomberg
Bloomberg reported that Guardant Health Inc (NASDAQ: GH) is reportedly exploring an acquisition of NeoGenomics Inc (NASDAQ: NEO), citing people familiar... 
Via Benzinga
NeoGenomics' Liquid Biopsy Subsidiary Inivata and Collaborators to Present Data that Further Validate the Application of its RaDaR(TM) MRD and InVisionFirst(R)-Lung Assays at the ESMO Congress 2021
FT MYERS, FL / ACCESSWIRE / September 9, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Product Safety
NeoGenomics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
FT. MYERS, FL / ACCESSWIRE / September 1, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing services and global oncology contract research services, today... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Earnings Scheduled For August 12, 2021
Companies Reporting Before The Bell • Anavex Life Sciences (NASDAQ:AVXL) is estimated to report earnings for its third quarter. • ITeos Therapeutics (NASDAQ:ITOS... 
Via Benzinga
NeoGenomics, inc (NEO) Q2 2021 Earnings Call Transcript
NEO earnings call for the period ending June 30, 2021. 
Via The Motley Fool
Topics Earnings
Exposures Financial
NeoGenomics Q2 Earnings Helped By Higher Test Volume; Backs FY21 Guidance
NeoGenomics Inc (NASDAQ: NEO) reported Q2 revenue of $122 million, +40% Y/Y, beating the consensus of $118.16 million. Clinical Services revenue of $101 million... 
Via Benzinga
NeoGenomics Reports 40% Revenue Growth to $122 Million in the Second Quarter
Second-Quarter 2021 Results and Highlights: - Consolidated revenue increased 40% to $122 million - Clinical Services revenue increased 37% to $101 million - Pharma Services revenue increased 55% to $20... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance Retirement
Exposures COVID-19 Legal Pension
NeoGenomics Schedules its Second Quarter 2021 Earnings Release for August 6, 2021
FT. MYERS, FL / ACCESSWIRE / July 14, 2021 / NeoGenomics, Inc. (NASDAQ:NEO), a leading provider of cancer-focused genetic testing and global contract research services, announced today that it plans to... 
From NeoGenomics, Inc.
Via AccessWire
Topics Regulatory Compliance
Exposures COVID-19 Legal Regulatory
Earnings Scheduled For August 6, 2021
Companies Reporting Before The Bell • Liberty Braves Group (NASDAQ:BATRA) is projected to report quarterly loss at $0.03 per share on revenue of $154.00 million.... 
Via Benzinga
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.